Centene (CNC) Expected to Announce Earnings on Wednesday

Centene (NYSE:CNC) is expected to be posting its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Centene to post earnings of ($0.18) per share and revenue of $47.5021 billion for the quarter. Centene has set its FY 2025 guidance at 1.750-1.750 EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 9:00 AM ET.

Centene (NYSE:CNC) last issued its quarterly earnings data on Friday, July 25th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.39). The business had revenue of $48.74 billion for the quarter, compared to the consensus estimate of $44.71 billion. Centene had a net margin of 1.15% and a return on equity of 9.57%. Centene’s revenue was up 22.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.42 EPS. On average, analysts expect Centene to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Centene Stock Performance

CNC stock opened at $36.10 on Wednesday. The firm has a 50 day moving average of $32.57 and a two-hundred day moving average of $43.27. Centene has a 12 month low of $25.08 and a 12 month high of $70.11. The company has a market capitalization of $17.73 billion, a price-to-earnings ratio of 8.94, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64.

Insider Activity

In other news, Director Theodore R. Samuels II acquired 9,000 shares of Centene stock in a transaction on Monday, July 28th. The stock was bought at an average price of $27.62 per share, for a total transaction of $248,580.00. Following the transaction, the director owned 32,000 shares of the company’s stock, valued at $883,840. The trade was a 39.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sarah London acquired 19,230 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were purchased at an average cost of $25.50 per share, for a total transaction of $490,365.00. Following the acquisition, the chief executive officer directly owned 845,275 shares in the company, valued at $21,554,512.50. This represents a 2.33% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Centene

Institutional investors and hedge funds have recently bought and sold shares of the business. B. Riley Wealth Advisors Inc. acquired a new position in shares of Centene in the 2nd quarter valued at $281,000. Advisory Services Network LLC increased its stake in Centene by 352.6% in the second quarter. Advisory Services Network LLC now owns 16,747 shares of the company’s stock valued at $909,000 after acquiring an additional 13,047 shares during the period. Geneos Wealth Management Inc. raised its position in Centene by 29.8% in the second quarter. Geneos Wealth Management Inc. now owns 1,897 shares of the company’s stock worth $103,000 after purchasing an additional 435 shares in the last quarter. Caxton Associates LLP boosted its holdings in Centene by 21.4% during the second quarter. Caxton Associates LLP now owns 7,291 shares of the company’s stock valued at $396,000 after purchasing an additional 1,283 shares in the last quarter. Finally, Headlands Technologies LLC grew its stake in shares of Centene by 1,236.2% in the 2nd quarter. Headlands Technologies LLC now owns 3,247 shares of the company’s stock valued at $176,000 after purchasing an additional 3,004 shares during the period. Institutional investors own 93.63% of the company’s stock.

Analysts Set New Price Targets

CNC has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Centene from $48.00 to $30.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 29th. Mizuho upped their price target on Centene from $28.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, October 9th. Bank of America downgraded Centene from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $52.00 to $30.00 in a research note on Wednesday, July 16th. Robert W. Baird decreased their target price on Centene from $68.00 to $28.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Finally, Barclays lifted their price target on shares of Centene from $33.00 to $35.00 and gave the company an “equal weight” rating in a research report on Friday, September 12th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $39.50.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.